DDInter1702 DDInter624
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Sorafenib {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Sorafenib {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Sorafenib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Sorafenib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Nevirapine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Lopinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Nevirapine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Sorafenib {u} (Compound) upregulates {v} (Gene) WARS
WARS {u} (Gene) is upregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Sorafenib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Sorafenib (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Efavirenz (Compound)
Sorafenib (Compound) binds KIT (Gene) and KIT (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Sorafenib (Compound) binds KIT (Gene) and KIT (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Efavirenz (Compound)
Sorafenib (Compound) upregulates WARS (Gene) and WARS (Gene) is upregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)